Loading
Immunotherapy and Immune Responses / Cancer Research and Treatments · Journal article
World Journal of Oncology · September 5, 2026
Encouraging direction, but not yet definitive.
This preclinical study in C57BL/6 mice bearing low PD-L1 Lewis lung carcinoma demonstrates that a RAD001-adjuvanted influenza vaccine synergizes with anti-PD-1 monotherapy to improve tumor growth control and survival, accompanied by enhanced CD8+ T-cell infiltration and a Th1-shifted cytokine profile, without reported organ toxicity. The findings suggest immunological mechanism and safety in a defined murine model but require clinical validation before human application.
Randomized controlled preclinical study in murine syngeneic tumor model. C57BL/6 mice bearing Lewis lung carcinoma tumors characterized by low PD-L1 expression (10.28%).. Intervention: Anti-PD-1 therapy combined with RAD001-adjuvanted influenza vaccine. Compared with: Control, anti-PD-1 monotherapy, anti-PD-1 plus split influenza vaccine, and anti-PD-1 plus MF59-adjuvanted vaccine.
RAD001-adjuvanted vaccine combined with anti-PD-1 achieved superior tumor growth inhibition compared to all other treatment groups including anti-PD-1 monotherapy and MF59-adjuvanted vaccine combination Increased CD8+ T-cell infiltration and higher CD8+/regulatory T-cell ratio observed in RAD001 + anti-PD-1 group versus controls Serum cytokine analysis showed a trend toward increased interferon-gamma and interleukin-2, consistent with Th1-dominant profile
No treatment-related toxicities detected on histopathological examination of heart, liver, lungs, kidneys, or spleen
The combination strategy may offer a rationale for clinical trials in patients with PD-L1-low or immunologically cold lung cancers, but this is a single preclinical model and does not yet support human use. The immunological mechanisms identified warrant further investigation in human studies.
A mechanistic preclinical study in a murine model showing synergistic efficacy of a novel vaccine-adjuvant combination with PD-1 blockade, with supporting immunological data but requiring clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
The combination strategy may offer a rationale for clinical trials in patients with PD-L1-low or immunologically cold lung cancers, but this is a single preclinical model and does not yet support human use. The immunological mechanisms identified warrant further investigation in human studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have transformed lung cancer therapy, but their efficacy is often limited in tumors with low programmed cell death ligand 1 (PD-L1) expression and immunologically “cold” tumor microenvironments. This study aimed to evaluate the safety and therapeutic efficacy of combining a RAD001-adjuvanted influenza vaccine with PD-1 blockade and to explore its immunological mechanisms in a murine lung cancer model. Methods: C57BL/6 mice bearing Lewis lung carcinoma (LLC) tumors, characterized by low PD-L1 levels (10.28%), were randomized to receive control, anti-PD-1 monotherapy, or anti-PD-1 combined with either a split influenza vaccine, an MF59-adjuvanted vaccine, or a RAD001-adjuvanted vaccine. Primary endpoints included tumor growth kinetics and survival. Safety was assessed via histopathological analysis of major organs and biochemical analyses. Mechanistic changes were evaluated through immunophenotyping of tumor-infiltrating lymphocytes (TILs) and serum cytokine profiling. Results: The RAD001-adjuvanted vaccine synergized with anti-PD-1 therapy, resulting in superior tumor growth inhibition compared to all other groups. This synergy was associated with a remodeled tumor microenvironment, showing increased CD8+ T-cell infiltration and a higher CD8+/regulatory T-cell ratio. Serum analysis revealed a shift toward a Th1-dominant cytokine profile (a trend toward increased interferon-gamma and interleukin-2). Histopathological and biochemical examination confirmed no treatment-related toxicities in the heart, liver, lungs, kidneys, or spleen. Conclusions: RAD001-adjuvanted influenza vaccination safely enhances the efficacy of anti-PD-1 therapy in PD-L1–low murine lung cancer by promoting a pro-inflammatory immune microenvironment. These findings suggest that strategic vaccine adjuvant selection can broaden the therapeutic reach of immune checkpoint inhibitors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.